Oric Pharmaceuticals Inc. (ORIC) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $9.24 (+2.78% 1D, market cap $931.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ORIC ranks #871 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORIC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -33.4%. By comparison, AKTS (Aktis Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $937.2M) and CYRX (CryoPort Inc.) posts a D- grade (43/100 RQD, P/E 11.8x, ROIC -11.5%, cap $926.4M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
Per ORIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001796280), Oric Pharmaceuticals Inc. generated $0 in revenue, -$129.5M in net income, and -$111.7M in free cash flow against $408.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ORIC currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.36) and Max Pain ($9.70) forces dealer call-delta covering toward $15.41.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Oric Pharmaceuticals Inc. (ORIC) surged +2.78% to $9.24, trading at 27% of its 52-week range ($7.23 – $14.68). Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ORIC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ORIC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Oric Pharmaceuticals Inc. (ORIC) ranks #871 by composite RQD confidence (29/100, grade E) and #371 by equity capitalization ($931.8M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. CYRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ORIC at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ORIC
ACTIVE
Oric Pharmaceuticals Inc. | E | 29/100 | — | — | -33.4% | +2.78% | $931.8M | Benchmark Subject |
| AKTS Aktis Oncology Inc. | D- | 41/100 | — | — | — | -5.46% | $937.2M | /akts-vs-oric → |
| CYRX CryoPort Inc. | D- | 43/100 | 11.8x | 47.1% | -11.5% | -5.47% | $926.4M | /cyrx-vs-oric → |
| KURA Kura Oncology Inc. | E | 32/100 | — | — | -35.0% | -2.84% | $939.4M | /kura-vs-oric → |
| ANRO Alto Neuroscience Inc. | D- | 35/100 | — | — | -35.0% | -3.71% | $921.0M | /anro-vs-oric → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oric Pharmaceuticals Inc. (ORIC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$129.5M, operating cash flow of -$111.0M, and free cash flow of -$111.7M (+1.9% YoY). On the balance sheet, ORIC closed FY2025 with $408.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$129.5M | -$111.0M | -$111.7M | $408.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$127.8M | -$112.7M | -$113.8M | $274.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$100.7M | -$85.7M | -$85.7M | — | — |
As of 2026-11-02, Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $9.24 (+2.78% 1D, market cap $931.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ORIC ranks #871 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORIC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -33.4%. By comparison, AKTS (Aktis Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $937.2M) and CYRX (CryoPort Inc.) posts a D- grade (43/100 RQD, P/E 11.8x, ROIC -11.5%, cap $926.4M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
Per ORIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001796280), Oric Pharmaceuticals Inc. generated $0 in revenue, -$129.5M in net income, and -$111.7M in free cash flow against $408.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ORIC last traded at $9.24 (+2.78% on volume of 2,441,686 shares), positioning the stock -25.24% below its 50-day simple moving average ($12.36) and -16.98% below its 200-day simple moving average ($11.13). Across its 52-week range of $7.23 to $14.68, ORIC sits at the 27.0% percentile with a 14-day RSI of 31.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.08 to $10.40).
Why ORIC Stock surged +2.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ORIC scores 29 out of 100, graded E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Taken together, the rating frames ORIC as carrying elevated forensic and fundamental risk with weak institutional and insider signals. A prospective investor should weigh the cash-burn profile heavily against any upside thesis that depends on future clinical or commercial milestones, none of which are quantified in the source data.
Oric Pharmaceuticals Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M across the FY 2023–FY 2025 periods shown in the SEC financials. Market capitalization is $0.9B per the profile.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-143.0M | $-129.5M | N/A | $-111.7M | $45.7M | N/A |
| FY 2024 | $0.0M | $-142.9M | $-127.8M | N/A | $-113.8M | $59.4M | N/A |
| FY 2023 | $0.0M | $-110.8M | $-100.7M | N/A | $-85.7M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M in each period and operating income and net income are negative throughout. Gross, operating, and net margins are each recorded as 0% in the market data. Per the Roarable RQD rating, ROIC is -33.4% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 2/9. Reported cash declined from $59.4M in FY 2024 to $45.7M in FY 2025, and debt is not available in source data.
Per the recent news wire, the feed includes several market-wire and catalyst items:
Risk watch items include the CFO share sale and the mixed signal set (two GREEN catalyst items against several YELLOW market-wire items). The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for ORIC. Within the stated sector (Health Care) and industry (Biotechnology: Pharmaceutical Preparations), a prospective investor would ordinarily watch for 2nd-order bottlenecks in clinical, manufacturing, and partnering relationships; the source data does not confirm any of these for ORIC.
Per the analyst data and holders sections, no analyst or holder data is available in the source data. Analyst price-target references appear only in the news wire: Wedbush (Outperform, $14 price target) and Stifel (Buy, $18 price target). Consensus rating, count of analysts, and 13F, Form 4, or Congressional holder detail are not available in source data beyond the CFO share-sale headline in the news wire.
Real-time company headlines, analyst actions, and sector developments for Oric Pharmaceuticals Inc. (ORIC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Oric Pharmaceuticals Inc. (ORIC) market action, institutional positioning, and fundamental catalysts.
Welcome to the ORIC (Oric Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ORIC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Oric Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ORIC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.99 (52-wk range $7.23 - $14.68), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).